Lilly says Zepbound trial cut adolescents’ weight by about 18 kg on average
Health · Sunday, November 22, 2026 · 4 sources

Lilly says Zepbound trial cut adolescents’ weight by about 18 kg on average

Eli Lilly says adolescents aged 12 to 17 with obesity lost an average of 40 pounds (about 18 kg) in a clinical trial of Zepbound, its weight-loss drug. Lilly’s phase III study enrolled 160 participants and is testing weekly tirzepatide; its trial listing says the study runs until July 2029, so the reported results do not establish approval for adolescents.

Bottom line — Lilly’s adolescent trial is still listed as ongoing, and Zepbound is not approved for children.

Go deeper 5

  1. Lilly’s trial listing gives an age range of 12 to 17 and an enrolment goal of 160.

  2. The study is testing tirzepatide once a week against a possible placebo.

  3. The primary study is planned to last about 90 weeks, with an optional extension of up to 160 weeks, according to Lilly.

  4. Lilly’s trial criteria include obesity, or overweight with at least one weight-related condition; participants must also have started puberty.

  5. Lilly says Zepbound is not known to be safe and effective for use in children.

Read the reporting 4

dstld. Your daily news summary designed to surface the news that matters from a European perspective. Curated by humans, summarized by AI - always with links back to the original reporting.

Links · Contact
Popular topics · WorldEuropeGamesAI
Last generated: Nov 22, 7:07 PM UTC by wreetco

dstld. Your daily news summary designed to surface the news that matters from a European perspective. Curated by humans, summarized by AI - always with links back to the original reporting.

Links · Contact
Popular topics · WorldEuropeGamesAI
Last generated: Nov 22, 7:07 PM UTC by wreetco